By Mark DaCosta- In an encouraging development in the pressing battle against malaria, the World Health Organisation (WHO) has announced, on April 21, a historic prequalification for a medicine designed specifically to treat newborns and young infants weighing between two and five kilograms.
As World Malaria Day is here on April 25, this significant milestone not only highlights the global efforts to tackle malaria but also shines a light on the urgent need for tailored healthcare solutions for the most vulnerable, particularly in our nation, where the fight against malaria remains critical.
The newly prequalified treatment, artemether-lumefantrine, is a landmark achievement in paediatric care for malaria, as historically, infants have been prescribed medications intended for older children or adults, which has led to increased risks of misdosing and adverse side effects. This prequalification means that the drug has been vetted, by scientific experts, to meet high international standards of quality, safety, and efficacy, paving the way for wider access in malaria-endemic regions, including our country’s impoverished interior areas, where medical resources are often scarce.
Dr Tedros Adhanom Ghebreyesus, WHO’s Director-General, emphasised the urgency of the matter, stating, “Malaria has stolen children from their parents, and health, wealth and hope from communities. Ending malaria in our lifetime is no longer a dream – it is a real possibility.”
In Guyana, the stakes are particularly high. The Ministry of Health reported 24,169 malaria cases in 2024, reflecting a substantial public health burden. Regions such as Barima-Waini and Upper Takutu-Upper Essequibo are disproportionately affected, while coastal areas remain relatively stable.
The geographical disparity highlights the importance of targeted interventions tailored to the needs of specific communities, particularly in the interior regions. The prequalified treatment will potentially fill a critical gap in provision, offering hope to the approximately 30 million newborns worldwide who are exposed to malaria each year.
Prequalification, in this context, is a rigorous assessment by the WHO to ensure that a treatment meets the essential criteria for quality and safety before it can be distributed in public health programmes. Gaining this designation is a crucial step towards widening access to lifesaving medications, especially for those who are most susceptible to severe disease outcomes, such as children under five and pregnant women.
Moreover, as WHO and its partners observe World Malaria Day, this year’s campaign theme, “Driven to End Malaria: Now We Can. Now We Must,” acts as a loud call. It encourages nations, including ours, to seize the moment and intensify efforts in combating this preventable disease. The significance of World Malaria Day extends beyond mere awareness; it serves to mobilise political support, funding, and community action at local and international levels.
The current scenario calls for urgent attention as the WHO recently reported that global progress is stalling due to challenges such as drug and insecticide resistance. In fact, parts of the Horn of Africa have experienced alarming rates of testing failures, resulting in misdiagnoses and improperly treated cases. The new diagnostic tests being rolled out aim to address these gaps and ensure accurate detection of malaria, further reinforcing the critical nature of the prequalified treatment for infants.
Despite the existing challenges, substantial progress has been made since the year 2000 — millions of infections have been prevented, and lives saved globally. Yet, as we reflect on these successes, we must also critically examine the obstacles that remain, especially as a nation striving for improvement in healthcare delivery. The PPP government’s handling of healthcare resources and public health initiatives raises questions, particularly in light of the need for comprehensive strategies that prioritise vulnerable populations and underfunded regions, which remain largely neglected.
The larger context of Guyana’s malaria burden reveals a complicated intertwining of social and economic factors. The interior regions, rich in natural resources, often experience a surge in malaria due to increased exposure through occupations like mining, which sees young men, particularly indigenous Amerindians, face significant exposure risks. With limited access to healthcare services, this demographic represents a large portion of those affected by malaria, underscoring the urgent need for effective healthcare interventions.
As our nation commemorates World Malaria Day, it is clear, and the experts agree, the fight against malaria requires sustained political will and financial commitment. The new prequalified treatment is a beacon of hope but should also serve as a reminder of the responsibilities that lie with our government to ensure equitable healthcare access for all citizens, particularly those in high-risk areas. The challenge ahead necessitates multi-faceted solutions, underscored by a commitment to community engagement and the empowerment of local health systems.
The WHO’s announcement presents a pivotal moment in our ongoing battle against malaria, particularly for our youngest and most vulnerable. With the prequalification of artemether-lumefantrine, there is optimism that targeted interventions in our nation’s most impacted regions can lead to tangible reductions in malaria morbidity and mortality
